Bruce Morimoto
Head, Drug Development Fuku Biotech
Seminars
Thursday 5th February 2026
Roundtable Discussion: Digital Wearable Sensors to Provide Continuous, Objective Motor Data & Unlock Faster, Leaner Parkinson’s Trials as Primary Endpoints
1:30 pm
- Capturing wrist worn and smartphone sensor streams that continuously log tremor, bradykinesia, and gait, supplying objective high frequency data that can shrink sample sizes and sharpen signal detection
- Highlighting the first regulated Parkinson’s study to use a digital movement biomarker as its primary outcome, setting a clear regulatory precedent that boosts sponsor confidence to adopt wearables in future trials
Thursday 5th February 2026
Panel Discussion: Patient Perspectives in Neurodegeneration: Shaping the Future of Alzheimer’s & Parkinson’s Drug Development
8:30 am
- Hear directly from individuals living with Alzheimer’s and Parkinson’s alongside leading foundations, offering a unified view of lived experience and scientific context
- Explore real-world treatment challenges, clinical trial barriers, and the outcomes that matter most to patients across both diseases
- Gain actionable, patient-driven insights to inform more inclusive, meaningful, and effective drug development and trial design
Wednesday 4th February 2026
Panel Discussion: From Proteinopathies to Pathways: The Next Wave of Disease-Modifying Therapies in AD & PD – Beyond Aβ, Tau & α-Synuclein
8:30 am
- How do we move beyond targeting amyloid, tau, and α-synuclein to intervene earlier in the disease cascade through pathways like neuroinflammation, lysosomal dysfunction, and mitochondrial stress?
- What evidence is now required to prove disease modification in the clinic, and how can diagnostic, target-engagement, and progression biomarkers be aligned to make this measurable and regulatory-credible?
- Where does precision neurology realistically stand today, and how far can patient subtyping and enrichment strategies go before regulatory and operational constraints take over?
- When do combination and mixed-modality approaches outperform single mechanisms, and how can they be designed to deliver more durable, scalable disease-modifying impact?
Thursday 5th February 2026
Panel Discussion: Bridging Innovation & Investment: De-Risking Disease-Modifying Neurodegenerative Therapies to Secure Investor Backing
3:30 pm
- What does “de-risked” biology actually mean in AD/PD right now, and how does that differ for first-in-class versus best-in-class programs?
- In today’s market, what milestones genuinely unlock the next cheque: target validation, Phase 1 biomarkers, early clinical signal, or differentiated strategy vs the competitive landscape?
- How are investors underwriting differentiation in crowded spaces (e.g., brain-shuttle Aβ), and what must a Phase 1 package prove to stand out?
- Beyond science, what determines investability: team quality, trial execution, commercial fit, and the ability to pivot, and why do these factors now carry more weight than ever?
Thursday 5th February 2026
Chair’s Opening Remarks
8:25 am
Wednesday 4th February 2026
Chair’s Opening Remarks
8:25 am
Thursday 5th February 2026
Chair’s Closing Remarks & End of Conference
4:15 pm
Wednesday 4th February 2026
Chair’s Closing Remarks
5:00 pm
Thursday 5th February 2026
Chair:
Thursday 5th February 2026
Chair:
